Применение эверолимуса после трансплантации печени в реальной клинической практике по данным одного центра
https://doi.org/10.15825/1995-1191-2017-2-34-40
Аннотация
Ключевые слова
Об авторах
О. А. ГерасимоваРоссия
Д. А. Гранов
Россия
Ф. К. Жеребцов
Россия
Список литературы
1. Bilbao I, Dopazo C, Lazaro J, Castells L, Caralt M, Sapisochin G et al. Multiple indications for everolimus after liver transplantation in current clinical practice. World J. Transplant. 2014 June 24; 4 (2): 122–132. PMID: 25032101. doi: 10.5500/wjt.v4.i2.122.
2. Fortin MC, Raymond MA, Madore F, Fugère JA, Pâ quet M, St-Louis G et al. Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination. Am. J. Transplant. 2004; 4: 946–952. PMID: 15147429. doi: 10.1111/j.1600-6143.2004.00428.x.
3. Eisen HJ, Tuzcu EM, Dorent R, Kobashigawa J, Mancini D, Valantine-von Kaeppler HA et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N. Engl. J. Med. 2003; 349: 847–858. PMID: 12944570. doi: 10.1056/NEJMoa022171.
4. Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl. Int. 2007; 20: 27–36. PMID: 17181650. doi: 10.1111/j.1432-2277.2006.00414.x.
5. Saliba F, De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S et al. Renal function at two years in liver transplant patients receiving everolimus: results of a randomized, multicenter study. Am. J. Transplant. 2013; 13: 1734–1745. PMID: 23714399. doi: 10.1111/ajt.12280.
6. Schuurman HJ, Zenke G, Zerwes HG, Schreier MH. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997; 64: 36–42. PMID: 9233698.
7. Dumont FJ. Everolimus. Novartis. Curr Opin. Investig Drugs. 2001; 2: 1220–1234. PMID: 11717808.
8. Bilbao I, Sapisochin G, Dopazo C, Lazaro JL, Pou L, Castells L et al. Indications and management of everolimus after liver transplantation. Transplant. Proc. 2009; 41: 2172–2176. PMID: 19715864. doi: 10.1016/j.transproceed.2009.06.087.
9. Nielsen D, Briem-Richter A, Sornsakrin M, Fischer L, Nashan B et al. The use of everolimus in pediatric liver transplant recipients: first experience in a single center. Pediatr. Transplant. 2011; 15: 510–514. PMID: 21696525. doi:10.1111/j.1399-3046.2011.01515.
10. Saliba F, Dharancy S, Lorho R, Conti F, Radenne S et al. Conversion to everolimus in maintenance liver transplant patients: a multicenter, retrospective analysis. Liver Transpl. 2011; 17 (8): 905–913. doi: 10.1002/lt.22292. PMID: 21384525.
11. Masetti M, Rompianesi G, Montalti R, Romano A, Spaggiari M, Ballarin R et al. Effects of everolimus monotherapy on hematological parameters and iron homeostasis in de novo liver transplant recipients: preliminary results. Transplant. Proc. 2008; 40: 1947–1949. PMID: 18675097. doi: 10.1016/j.transproceed.2008.05.068.
12. Schrader J, Sterneck M, Klose H, Lohse AW, Nashan B, Fischer L. Everolimus-induced pneumonitis: report of the first case in a liver transplant recipient and review of treatment options. Transpl. Int. 2010; 23: 110–113. PMID: 19497063. doi: 10.1111/j.1432-2277.2009.00900.
13. Герасимова ОА, Жеребцов ФК, Филиппенко МО, Гранов ДА. Первый опыт применения эверолимуса после трансплантации трупной печени. Вестник трансплантологии и искусственных органов. 2014; 16: 120. Gerasimova JA, Zherabtsov FK, Filippenko MO, Granov DA. Perviy opyt primenenia everolimusa posle transpalantacii trypnoy pecheni. Vestnik transplantologii i iskusstvennych organov. 2014; 16: 120.
14. EASL Clinical Practice Guidelines: Liver Transplantation. J. Hepatol. 2016; 64 (2): 433–485. doi: 10.1016/j.jhep.2015.10.006.
15. Gastroagudin JF, Molina E, Romero R, Otero E, Tomé S, Varo E. Improvement of renal function after from a calcineurini inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009; 15: 1792–1797. PMID: 19938140. doi: 10.1002/lt.21920.
16. De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl. 2009; 15: 1262–1269. PMID: 19790150. doi: 10.1002/lt.21827.
17. Fisher L, Klempnauer J, Beckebaum S, Metselaar HJ, Neuhaus P, Schemmer P et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation – PROTECT. Am. J. Transplant. 2012; 12: 1855–1865. doi: 10.1111/j.1600-6143.2012.04049.x. PMID: 22494671.
18. Sterneck M, Kaiser GM, Heyne N, Richter N, Rauchfuss F, Pascher A et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am. J. Transplant. 2014; 14: 701–710. PMID: 24502384. doi: 10.1111/ajt.12615.
19. De Simone P, Nevens F, De Carlis L, Metselaar HJ, Beckebaum S, Saliba F, Jonas S et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am. J. Transplant. 2012; 12: 3008–3020. doi: 10.1111/j.1600-6143.2012.04212.x. PMID: 22882750.
20. Saliba F, Duvoux C, Gugenheim J, Kamar N, Dharancy S, Salamé E et al. Efficacy and safety of everolimus and mycophenolic acid with early tacrolimus withdrawal after liver transplantation: A multicenter, randomized trial. Am. J. Transplant. 2017; 30. doi: 10.1111/ajt.14212. [Epub ahead of print] PubMed PMID: 28133906.
21. Willamil FG, Gadano AC, Zingale F, Perez R, Gil O, Yantorno S et al. Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcinerin inhibitors. Liver Int. 2014; 10: 1513–1521. doi: 10.1111/liv.12416. PMID: 25453134.
22. Saliba F, Nevens F. Progression of liver fibrosis in HCVpositive liver transplant recipients randomized to everolimus with reduced calcineurin inhibitor (CNI) therapy or a standard CNI regimen. Liver Int. 2015; 38: 373–374. PMID: 25207429. doi: 10.1111/tri.12449.
23. De Simone P, Fagiuoli S, Cescon M, De Carlis L, Tisone G, Volpes R et al. Use of everolimus in liver transplantation: Recommendations From a Working Group. Transplantation. 2017; 101 (2): 239–251. Published online 2016 Jul 28. doi: 10.1097/TP.0000000000001438. PMID: 27495768.
Рецензия
Для цитирования:
Герасимова О.А., Гранов Д.А., Жеребцов Ф.К. Применение эверолимуса после трансплантации печени в реальной клинической практике по данным одного центра. Вестник трансплантологии и искусственных органов. 2017;19(2):34-40. https://doi.org/10.15825/1995-1191-2017-2-34-40
For citation:
Gerasimova O.A., Granov D.A., Zherebtsov F.K. Everolimus in clinical practice after liver transplantation: a single-center experience. Russian Journal of Transplantology and Artificial Organs. 2017;19(2):34-40. (In Russ.) https://doi.org/10.15825/1995-1191-2017-2-34-40